natgillin/translations-raw huggingface dataset:
Abdominal pain; Constipation; Diarrhoea; Nausea
bolečine v trebuhu, zaprtje, diareja, navzea
abdominal pain; dry mouth; indigestion, bloating; numbness of the mouth
bolečine v predelu trebuha, suha usta, slaba prebava, napenjanje, odrevenelost ust
Abdominal pain; Dyspepsia; Gastrointestinal haemorrhage (G3/4: 0.6%)
bolečine v trebuhu, dispepsija, krvavitev v prebavilih (S3/4: 0,6 %)
abdominal pain; uncomfortable feeling in the stomach or belching after eating; constipation; full or bloated feeling in the stomach; diarrhoea; flatulence,
bolečine v trebuhu, neprijeten občutek v želodcu ali spahovanje po jedi, zaprtje, občutek polnega ali napihnjenega želodca, driska, vetrovi
Abdominal paina
bolečine v trebuhua
Abdominal painC, diarrhoea, dyspepsiaD, gastritisD, nauseaC, vomitingD
bolečine v trebuhuC, driska, dispepsijaD, gastritisD, navzeaC, bruhanjeD
Abdominal paine
bolečine v trebuhue
Abdominal painf
Bolečina v trebuhuf
Abdominal palpation should be sufficient to detect abnormal increases in splenic volume.
Za ugotavljanje nenormalnega povečanja volumna vranice bi morala zadoščati palpacija trebuha.
abdominal pressure
bolečine v trebuhu
abdominal pressure
tiščanje v trebuhu
abdominal stiffness, stomach pain, vomiting blood
trd trebuh, bolečine v trebuhu, krvavo bruhanje,
abdominal swelling
oteklina trebuha
Abdominal swelling or bloating,
napihnjenost ali napenjanje v trebuhu,
abdominal symptoms (such as vomiting, indigestion, constipation), rectal bleeding;
trebušni simptomi (npr. bruhanje, prebavne težave, zaprtje), krvavitve v danko;
Abdominal tenderness*
oralna parestezija občutljivost trebuha
Abdominal tenderness, anal fissure, anal spasm, cheilitis, cheilosis, colitis ulcerative, duodenal ulcer, duodenitis, dysphagia, gastric polyps, inguinal hernia, mouth ulceration, oesophagitis, oral pain, rectal polyp, rectal ulcer, stomach discomfort
občutljivost trebuha, analna fisura, analni spazem, heilitis, heiloza, ulcerativni kolitis, razjeda dvanajstnika, duodenitis, disfagija, želodčni polipi, dimeljska kila, razjede ustne sluznice, ezofagitis, bolečina v ustih, rektalni polip, rektalni ulkus, želodčne težave
Abdominal wall abscess.
absces v trebušni steni
Abdominal/stomach discomfort
neugodje v trebuhu/želodcu
ABILIFY 1 mg/ml oral solution
ABILIFY 1 mg/ml peroralna raztopina
ABILIFY 1 mg/ml oral solution aripiprazole
ABILIFY 1 mg/ml peroralna raztopina aripiprazol
ABILIFY 10 mg orodispersible tablets ABILIFY 15 mg orodispersible tablets ABILIFY 30 mg orodispersible tablets
ABILIFY 10 mg orodisperzibilne tablete ABILIFY 15 mg orodisperzibilne tablete ABILIFY 30 mg orodisperzibilne tablete
ABILIFY 10 mg orodispersible tablets are round and pink, marked with ‘"A" over "640"’ on one side and ‘10’ on the other.
ABILIFY 10 mg orodisperzibilne tablete so okrogle oblike in roza barve, označene z '"A" nad "640"' na eni strani in '10' na drugi.
ABILIFY 10 mg orodispersible tablets: Red iron oxide (E 172) ABILIFY 15 mg orodispersible tablets: Yellow iron oxide (E 172) ABILIFY 30 mg orodispersible tablets: Red iron oxide (E 172)
ABILIFY 10 mg orodisperzibilne tablete: rdeči železov oksid (E 172) ABILIFY 15 mg orodisperzibilne tablete: rumeni elezov oksid (E 172) ABILIFY 30 mg orodisperzibilne tablete: rdeči železov oksid (E 172)
ABILIFY 10 mg tablets are rectangular and pink, marked with ‘A-008’ and ‘10’ on one side.
Tablete ABILIFY 10 mg so pravokotne in roza, označene z 'A-008' in '10' na eni strani.
ABILIFY 15 mg tablets are round and yellow, marked with ‘A-009’ and ‘15’ on one side.
Tablete ABILIFY 15 mg so okrogle in rumene, označene z 'A-009' in '15' na eni strani.
ABILIFY 15 mg tablets: Yellow iron oxide (E 172) ABILIFY 30 mg tablets: Red iron oxide (E 172)
ABILIFY 15 mg tablete: rumeni železov oksid (E 172) ABILIFY 30 mg tablete: rdeči železov oksid (E 172)
ABILIFY 30 mg orodispersible tablets are round and pink, marked with ‘"A" over "643"’ on one side and ‘30’ on the other.
ABILIFY 30 mg orodisperzibilne tablete so okrogle oblike in roza barve, označene z '"A" nad "643"' na eni strani in '30' na drugi.
ABILIFY 30 mg tablets are round and pink, marked with ‘A-011’ and ‘30’ on one side.
Tablete ABILIFY 30 mg so okrogle in roza, označene z 'A-011' in '30' na eni strani.
ABILIFY 5 mg tablets are rectangular and blue, marked with ‘A-007’ and ‘5’ on one side.
Tablete ABILIFY 5 mg so pravokotne in modre, označene z 'A-007' in '5' na eni strani.
ABILIFY 5 mg tablets: Indigo carmine aluminium lake (E 132) ABILIFY 10 mg tablets: Red iron oxide (E 172)
ABILIFY 5 mg tablete: indigotin (E 132) ABILIFY 10 mg tablete: rdeči železov oksid (E 172)
ABILIFY 7.5 mg/ml solution for injection
ABILIFY 7,5 mg/ml raztopina za injiciranje
ABILIFY 7.5 mg/ml solution for injection aripiprazole
ABILIFY 7,5 mg/ml raztopina za injiciranje aripiprazol
Abilify also had a similar effect to haloperidol and to lithium over three weeks.
Zdravilo Abilify je imelo v treh tednih podoben učinek kot haloperidol in litij.
Abilify is also used for up to 12 weeks to treat moderate to severe manic episodes in patients aged 13 years or over.
Do 12 tednov se zdravilo uporablja tudi za zdravljenje zmernih do hudih maničnih epizod pri bolnikih, starih 13 let ali več.
ABILIFY is effective in a dose range of 10 to 30 mg/day.
Zdravilo ABILIFY je učinkovito v razponu odmerkov od 10 do 30 mg/dan.
Abilify is used in adults to treat moderate to severe manic episodes and to prevent new manic episodes in adults who have responded to the medicine in the past.
Zdravilo Abilify se uporablja pri odraslih bolnikih za zdravljenje zmernih in hudih maničnih epizod ter za preprečevanje pojava novih maničnih epizod pri bolnikih, ki so se v preteklosti že odzvali na zdravilo.
Abilify is used in patients aged 15 years or over; bipolar I disorder, a mental illness in which patients have manic episodes (periods of abnormally high mood), alternating with periods of normal mood.
Zdravilo Abilify se uporablja pri bolnikih, starih 15 let ali več; bipolarno motnjo I, tj. duševno boleznijo, pri kateri ima bolnik manične epizode (obdobja nenormalno privzdignjenega razpoloženja), ki se izmenjujejo z obdobji normalnega razpoloženja.
Abilify is used in patients with the following mental illnesses:
Zdravilo Abilify se uporablja pri bolnikih z naslednjimi duševnimi boleznimi:
Abilify Maintena 300 mg powder and solvent for prolonged-release suspension for injection Abilify Maintena 400 mg powder and solvent for prolonged-release suspension for injection Abilify Maintena 300 mg powder and solvent for prolonged-release suspension for injection in pre-filled syringe
Abilify Maintena 300 mg prašek in vehikel za suspenzijo za injiciranje s podaljšanim sproščanjem Abilify Maintena 400 mg prašek in vehikel za suspenzijo za injiciranje s podaljšanim sproščanjem Abilify Maintena 300 mg prašek in vehikel za suspenzijo za injiciranje s podaljšanim sproščanjem v napolnjeni injekcijski brizgi
Abilify Maintena 300 mg powder and solvent for prolonged-release suspension for injection Abilify Maintena 400 mg powder and solvent for prolonged-release suspension for injection Chemical and physical in-use stability has been demonstrated for 4 hours at 25°C. From a microbiological point of view, unless the method of opening/ reconstitution precludes the risk of microbial contamination, the product should be used immediately.
Abilify Maintena 300 mg prašek in vehikel za suspenzijo za injiciranje s podaljšanim sproščanjem Abilify Maintena 400 mg prašek in vehikel za suspenzijo za injiciranje s podaljšanim sproščanjem Zdravilo je med uporabo kemično in fizikalno stabilno 4 ure pri temperaturi 25 °C. Iz mikrobiološkega vidika je treba zdravilo uporabiti takoj, razen kadar način odpiranja/rekonstitucije preprečuje tveganje onesnaženja zdravila z mikrobi.
Abilify Maintena 300 mg powder and solvent for prolonged-release suspension for injection Abilify Maintena 400 mg powder and solvent for prolonged-release suspension for injection Powder and solvent for prolonged-release suspension for injection
Abilify Maintena 300 mg prašek in vehikel za suspenzijo za injiciranje s podaljšanim sproščanjem Abilify Maintena 400 mg prašek in vehikel za suspenzijo za injiciranje s podaljšanim sproščanjem Prašek in vehikel za suspenzijo za injiciranje s podaljšanim sproščanjem
Abilify Maintena 300 mg powder and solvent for prolonged-release suspension for injection EU/1/13/882/001
Abilify Maintena 300 mg prašek in vehikel za suspenzijo za injiciranje s podaljšanim sproščanjem
Abilify Maintena 300 mg powder and solvent for prolonged-release suspension for injection in pre-filled syringe aripiprazole
Abilify Maintena 300 mg prašek in vehikel za suspenzijo za injiciranje s podaljšanim sproščanjem v napolnjeni injekcijski brizgi. aripiprazol
Abilify Maintena 400 mg powder and solvent for prolonged-release suspension for injection EU/1/13/882/002
Abilify Maintena 400 mg prašek in vehikel za suspenzijo za injiciranje s podaljšanim sproščanjem
Abilify Maintena 400 mg powder and solvent for prolonged-release suspension for injection in pre-filled syringe aripiprazole
Abilify Maintena 400 mg prašek in vehikel za suspenzijo za injiciranje s podaljšanim sproščanjem v napolnjeni injekcijski brizgi. aripiprazol
Abilify Maintena contains the active substance aripiprazole and belongs to a group of medicines called antipsychotics.
Zdravilo Abilify Maintena vsebuje zdravilno učinkovino aripiprazol in spada v skupino zdravil, imenovanih antipsihotiki.
Abilify Maintena powder and solvent for prolonged-release suspension for injection
Abilify Maintena prašek in vehikel za suspenzijo za injiciranje s podaljšanim sproščanjem
ABILIFY oral solution can be taken regardless of meals.
Peroralno raztopino ABILIFY lahko jemljete ne glede na obroke.
ABILIFY oral solution contains fructose, sucrose and parahydroxybenzoates
Peroralna raztopina ABILIFY vsebuje fruktozo, saharozo in parahidroksibenzoate
ABILIFY oral solution contains the active substance aripiprazole and belongs to a group of medicines called antipsychotics.
Peroralna raztopina ABILIFY vsebuje zdravilno učinkovino aripiprazol in spada v skupino zdravil, imenovanih antipsihotiki.
ABILIFY oral solution is used to treat adults and adolescents aged 13 years and older who suffer from a condition with symptoms such as feeling "high", having excessive amounts of energy, needing much less sleep than usual, talking very quickly with racing ideas and sometimes severe irritability.
Peroralno raztopino ABILIFY uporabljamo za zdravljenje odraslih in mladostnikov, starih 13 let in več, ki imajo težave s simptomi, kot so evforično razpoloženje, pretirana energija, zmanjšana potreba po spanju, hitro govorjenje s prehitevajočimi mislimi in občasno huda razdražljivost.
ABILIFY oral solution with food, drink and alcohol
Zdravilo ABILIFY peroralna raztopina skupaj s hrano, pijačo in alkoholom
ABILIFY orodispersible tablets are supplied in perforated unit dose blisters packed in cartons containing 14 x 1, 28 x 1, or 49 x 1 orodispersible tablets.
ABILIFY orodisperzibilne tablete na voljo so v perforiranih pretisnih omotih v škatlah, ki vsebujejo po 14 x 1, 28 x 1 ali 49 x 1 orodisperzibilnih tablet.
ABILIFY orodispersible tablets are used to treat adults and adolescents aged 13 years and older who suffer from a condition with symptoms such as feeling "high", having excessive amounts of energy, needing much less sleep than usual, talking very quickly with racing ideas and sometimes severe irritability.
Zdravilo ABILIFY orodisperzibilne tablete uporabljamo za zdravljenje odraslih in mladostnikov, starih 13 let in več, ki imajo težave s simptomi, kot so evforično razpoloženje, pretirana energija, zmanjšana potreba po spanju, hitro govorjenje s prehitevajočimi mislimi in občasno huda razdražljivost.
ABILIFY orodispersible tablets contain aspartame
Zdravilo ABILIFY orodisperzibilne tablete vsebuje aspartam
ABILIFY orodispersible tablets contain aspartame, a source of phenylalanine which may be harmful for people with phenylketonuria.
Orodisperzibilne tablete ABILIFY vsebujejo aspartam; ta je vir fenilalanina, ki je lahko škodljiv za bolnike s fenilketonurijo.
ABILIFY orodispersible tablets contain lactose
Zdravilo ABILIFY orodisperzibilne tablete vsebuje laktozo
ABILIFY orodispersible tablets contain lactose.
Tablete ABILIFY vsebujejo laktozo.
ABILIFY orodispersible tablets contain the active substance aripiprazole and belong to a group of medicines called antipsychotics.
Zdravilo ABILIFY orodisperzibilne tablete vsebuje zdravilno učinkovino aripiprazol in spada v skupino zdravil, imenovanih antipsihotiki.
ABILIFY solution for injection contains the active substance aripiprazole and belongs to a group of medicines called antipsychotics.
Raztopina za injiciranje ABILIFY vsebuje zdravilno učinkovino aripiprazol in spada v skupino zdravil, imenovanih antipsihotiki.
ABILIFY solution for injection is given when treatment with oral formulations is not appropriate.
Raztopina za injiciranje ABILIFY uporabljamo, če zdravljenje s peroralnimi farmacevtskimi oblikami ni primerno.
ABILIFY solution for injection is ready to use.
ABILIFY raztopina za injiciranje je že pripravljena za uporabo.
ABILIFY solution for injection is used to treat quickly symptoms of agitation and distressing behaviour that may occur in a disease characterised by symptoms such as: hearing, seeing or sensing things which are not there, suspiciousness, mistaken beliefs, incoherent speech and behaviour and emotional flatness.
ABILIFY raztopino za injiciranje uporabljamo za hitro zdravljenje simptomov agitacije in vedenjskih sprememb, ki se lahko pojavijo pri bolezni, za katero so značilni simptomi, kot so: slišanje, videnje ali občutenje stvari, ki jih dejansko ni, sumničavost, zmotna prepričanja, nepovezano govorjenje in vedenje ter čustvena praznost.
Abilify solution for injection was compared with lorazepam (another antipsychotic medicine) and placebo over two hours in one study involving 301 patients experiencing symptoms of agitation.
Raztopino za injiciranje zdravila Abilify so v obdobju dveh ur primerjali z lorazepamom (drugim antipsihotičnim zdravilom) in placebom v eni študiji, v katero je bil vključen 301 bolnik s simptomi agitacije.
ABILIFY tablets are supplied in perforated unit dose blisters packed in cartons containing 14 x 1, 28 x 1, 49 x 1, 56 x 1, or 98 x 1 tablets.
Zdravilo ABILIFY tablete je na voljo v perforiranih pretisnih omotih v škatlah, ki vsebujejo po 14 x 1, 28 x 1, 49 x 1, 56 x 1 ali 98 x 1 tableto.
ABILIFY tablets are used to treat adults and adolescents aged 13 years and older who suffer from a condition with symptoms such as feeling "high", having excessive amounts of energy, needing much less sleep than usual, talking very quickly with racing ideas and sometimes severe irritability.
Zdravilo ABILIFY tablete uporabljamo za zdravljenje odraslih in mladostnikov, starih 13 let in več, ki imajo težave s simptomi, kot so evforično razpoloženje, pretirana energija, zmanjšana potreba po spanju, hitro govorjenje s prehitevajočimi mislimi in občasno huda razdražljivost.
ABILIFY tablets contain lactose
Zdravilo ABILIFY tablete vsebuje laktozo
ABILIFY tablets contain the active substance aripiprazole and belong to a group of medicines called antipsychotics.
Zdravilo ABILIFY tablete vsebuje zdravilno učinkovino aripiprazol in spada v skupino zdravil, imenovanih antipsihotiki.
Abilify tablets were also compared with placebo in one study involving 302 patients aged between 13 and 17 years.
Tablete zdravila Abilify so s placebom primerjali tudi v študiji, ki je vključevala 302 bolnika, stara od 13 do 17 let.
Abilify was also compared with placebo in one study involving 296 children and adolescents.
Zdravilo Abilify so s placebom primerjali v eni študiji, v katero je bilo vključenih 296 otrok in mladostnikov.
Abilify was also more effective than placebo at preventing manic episodes returning in previously treated adults for up to 74 weeks, and when it was used as an add-on to existing treatment.
Zdravilo Abilify je bilo učinkovitejše od placeba tudi pri preprečevanju ponovitve maničnih epizod v obdobju 74 tednov pri predhodno zdravljenih odraslih in ob njegovi uporabi kot dodatek obstoječemu zdravljenju.
Abilify was also more effective than placebo over six weeks in the study of adolescents, and the effect of Abilify was maintained for at least six months in patients aged over 15 years.
V študiji, v kateri so sodelovali mladostniki, je bilo zdravilo Abilify v šestih tednih zdravljenja učinkovitejše od placeba, njegov učinek pa je pri bolnikih, starejših od 15 let, trajal najmanj šest mesecev.
Abiraterone does this by blocking an enzyme called CYP17 found in the testes and elsewhere in the body.
Abirateron to doseže z zaviranjem encima, imenovanega CYP17, ki ga najdemo v modih in drugje v telesu.
Abiraterone is an inhibitor of the hepatic drug-metabolising enzymes CYP2D6 and CYP2C8.
Abirateron je zaviralec jetrnih encimov za presnovo zdravil CYP2D6 in CYP2C8.
ablation of high-grade dysplasia (HGD) in patients with Barrett's Oesophagus (BO).
Fotodinamično zdravljenje (PDT, photodynamic therapy) s PhotoBarrom je indicirano v primeru odprave displazije visoke stopnje (HGD, 'high-grade dysplasia) pri bolnikih z Barrettovim požiralnikom (BP).
Ablavar 0.25 mmol/ml solution for injection
Ablavar 0,25 mmol/ml raztopina za injiciranje
Ablavar 0.25 mmol/ml solution for intravenous use
Ablavar 0,25 mmol/ml raztopina za intravenozno uporabo
Ablavar can be associated with allergy-like reactions (anaphylactoid / hypersensitivity reactions) characterised by:- skin reactions, (cutaneous reactions)
Ablavar je lahko povezan z alergijam podobnimi reakcijami (anafilaktoidne ali preobčutljivostne reakcije), za katere so značilne:
Ablavar1 gadofosveset trisodium
Ablavar1 trinatrijev gadofosveset
Abnormal
videnje svetlobnih
abnormal
zvečano razmerje
Abnormal (not menstrual) vaginal bleeding without a known/diagnosed cause.
nenormalne (t.j. nemenstrualne) vaginalne krvavitve brez znanega oz. diagnosticiranega vzroka,
Abnormal arteries, scarring of the arteries, clotting in the arteries, narrowing of the arteries, temporary redness of the face/skin, swelling of the face
abnormalne arterije, brazgotinjenje arterij, strjevanje krvi v arterijah, zoženje svetline arterij, prehodna rdečina obraza/kože, oteklina obraza,
Abnormal balance of minerals in the body causing bone problems, bone inflammation, abnormal weakening of the bone leading to bone problems, inflammation of the lining of the joints, rare bone condition
neravnovesje mineralov v telesu, ki povzroči težave s kostmi, vnetje kosti, nenormalna oslabelost kosti, ki povzroči težave s kostmi, vnetje sklepne ovojnice, redke bolezni kosti,
Abnormal behaviour, confusional state, depressed mood, excitability, feelings of emotional and mental discomfort, feeling of seeing or hearing things that are not really there when you sleep
nenormalno vedenje, stanje zmedenosti, depresivno razpoloženje, vzdražljivost, občutki čustvenega in duševnega nelagodja, občutek videnja ali slišanja stvari med spanjem, ki jih v resnici ni,
Abnormal behaviour, depressed mood, emotional disorder, fear, nightmare
nenormalno vedenje, depresivno razpoloženje, čustvene motnje, strah, nočne more
abnormal behaviour, emotional disorder, fear, nightmare,
nenormalno vedenje, motnje čustvovanja, strah, nočne more,
abnormal behaviour, emotional disorder, fear, nightmare, tremor, decreased sensitivity to touch, numbness or tingling feeling, pain radiating along the course of one or more nerves, drowsiness,
nenormalno vedenje, čustvene motnje, strah, nočne more, tresenje, zmanjšana občutljivost na dotik, občutek odrevenelosti ali mravljincev, bolečina, ki seva vzdolž poteka enega ali več živcev, zaspanost,
abnormal blood clotting, clumping of cells, abnormal clotting factor, reduction in red blood cells which can make the skin pale and cause weakness or breathlessness, low level of lymphocytes a specific type of white blood cells (lymphopenia), feeling your heartbeat
nenormalni krvni strdki, zlepljanje celic, nenormalni faktorji strjevanja krvi, znižanje števila rdečih krvnih celic, zaradi česar je lahko koža bleda in kar povzroči oslabelost ali kratko sapo, nizko število limfocitov, posebne vrste belih krvnih celic (limfopenija), občutenje bitja srca,
abnormal blood electrolytes
nenormalne vrednosti elektrolitov v krvi
abnormal blood fibrinogen (abnormal blood clotting)
abnormalni krvni fibrinogen (nenormalno strjevanje krvi)
Abnormal blood fibrinogen, increased heart rate, increased alanine aminotransferase, increased aspartate aminotransferase, increased blood bilirubin, abnormal liver function test, increased blood triglycerides
nenormalne vrednosti fibrinogena v krvi, povečanje srčnega utripa, povečana vrednost alanin aminotransferaze, povečana vrednost aspartat aminotransferaze, povečana vrednost bilirubina v krvi, nenormalni rezultati testov delovanja jeter, povečana vrednost trigliceridov v krvi
abnormal blood measurements for sodium
nenormalne krvne vrednosti za natrij
abnormal blood measurements for sodium;
nenormalne krvne vrednosti za natrij;
Abnormal blood sugar or insulin levels
nenormalne koncentracije sladkorja ali insulina v krvi
Abnormal blood test results (increased levels of certain liver enzymes or bilirubin in the blood, and decreased kidney function test)
nenormalni rezultati krvnih testov (zvišane ravni nekaterih jetrnih encimov ali bilirubina v krvi in zmanjšan rezultat testa delovanja ledvic)
abnormal blood test results for liver function
nenormalni izvidi krvnih preiskav delovanja jeter,
abnormal blood test results related to creatine phosphokinase, an enzyme found mainly in heart, brain and skeletal muscle
nenormalni izvidi preiskav krvi, povezanih s kreatin-fosfokinazo, encimom, ki se nahaja večinoma v srcu, možganih in skeletnih mišicah,
abnormal blood test results, including increase in white blood cells, low potassium levels
nenavadni rezultati krvnih preiskav, vključno povečano število belih krvničk, nizke ravni kalija,
Abnormal blood test results: reduced protein or sugar, increased phosphate, increase of the enzyme lactate dehydrogenase
nenormalni izvidi preiskav krvi: znižanje koncentracije beljakovin ali sladkorja, zvišanje koncentracije fosfatov, zvišanje encima laktat dehidrogenaze,
Abnormal blood test results: reduced protein or sugar, increased phosphate, increase of the enzyme lactate dehydrogenase
nenormalni izvidi preiskav krvi: znižanje koncentracije beljakovin ali sladkorja, zvišanje koncentracije fosfatov, zvišanje encima laktat-dehidrogenaze,
abnormal blood test results: reduced protein or sugar, increased phosphate, increase of the enzyme lactate dehydrogenase
nenormalni rezultati krvnih preiskav: zmanjšanje beljakovin ali sladkorja v krvi, zvišanje fosfatov, zvišanje encima laktat-dehidrogenaze
abnormal blood tests (decreased white blood cells [leucopenia; neutropenia]); decreased red blood cells (anaemia)
nenormalne krvne preiskave (zmanjšano število belih krvničk levkopenija, nevtropenija), zmanjšano število rdečih krvničk (anemija)
Abnormal blood tests for the liver function
nenormalni krvni testi za jetrno funkcijo,
Abnormal blood tests including pancreatic and liver enzymes.
nenormalni izvidi krvnih preiskav, vključno z encimi trebušne slinavke in jeter
Abnormal blood tests of the liver have been seen in some people receiving Orkambi.
Pri nekaterih ljudeh, ki so jemali zdravilo Orkambi, so ugotovili nenormalne krvne izvide jetrnih preiskav.
Abnormal blood values related to the function of the liver, biliary system or pancreas
nenormalne vrednosti v krvi, povezane z delovanjem jeter, žolčnega sistema ali trebušne slinavke
abnormal brain function male and female infertility
nenormalno delovanje možganov neplodnost moških in žensk
Abnormal brain function, Parkinson-like symptoms, nerve injury resulting in numbness, pain, tingling or burning in the hands or feet
nenormalno delovanje možganov, simptomi, podobni parkinsonovi bolezni, poškodba živca, ki povzroči otrplost, bolečino, mravljinčenje ali pekoč občutek v dlaneh ali stopalih
abnormal breast enlargement, breast pain, milk secretion from breasts
nenormalno povečanje dojk, bolečina v dojkah, spontano odtekanje mleka iz dojke
Abnormal breast milk production
nenormalno nastajanje mleka
Abnormal breath
neobičajni zvoki pri